CA3161952A1 — Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
Assigned to Karuna Therapeutics Inc · Expires 2021-05-27 · 5y expired
What this patent protects
Provided herein is a method of treating schizophrenia or a disease related to schizophrenia in a patient in need thereof. The method comprises orally administering to the patient twice daily an oral pharmaceutical composition comprising a plurality of xanomeline beads comprising …
USPTO Abstract
Provided herein is a method of treating schizophrenia or a disease related to schizophrenia in a patient in need thereof. The method comprises orally administering to the patient twice daily an oral pharmaceutical composition comprising a plurality of xanomeline beads comprising xanomeline or a salt thereof, and plurality of trospium beads comprising a salt of trospium, via the titration scheme that comprises up-titration of the xanomeline, or a salt thereof, and the salt of trospium.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.